Cargando…

Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease

BACKGROUND: IgG4-related ophthalmic disease is a rare, newly recognized entity with high failure rates on first-line therapy of systemic corticosteroids and no other proven management options. Case Presentation. Here, we present the clinical course of a patient with IgG4 ophthalmic disease who achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabol, Rachel A., Bubenzer, Virginia, Moroz, Krzysztof, Halat, Shams, Dang, Audrey, Ferdinand, Keith, Traylor, Angela, Boyd, Carol, Harris, Kendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492922/
https://www.ncbi.nlm.nih.gov/pubmed/32963860
http://dx.doi.org/10.1155/2020/8873078
_version_ 1783582460927279104
author Sabol, Rachel A.
Bubenzer, Virginia
Moroz, Krzysztof
Halat, Shams
Dang, Audrey
Ferdinand, Keith
Traylor, Angela
Boyd, Carol
Harris, Kendra
author_facet Sabol, Rachel A.
Bubenzer, Virginia
Moroz, Krzysztof
Halat, Shams
Dang, Audrey
Ferdinand, Keith
Traylor, Angela
Boyd, Carol
Harris, Kendra
author_sort Sabol, Rachel A.
collection PubMed
description BACKGROUND: IgG4-related ophthalmic disease is a rare, newly recognized entity with high failure rates on first-line therapy of systemic corticosteroids and no other proven management options. Case Presentation. Here, we present the clinical course of a patient with IgG4 ophthalmic disease who achieved a favorable response from radiotherapy. Our patient initially presented with a history of recurrent painful flares of orbital inflammation, a pathologic diagnosis follicular lymphoid hyperplasia from a right lacrimal gland biopsy, and MRI imaging noting expansion of the lateral rectus muscle of the right eye. Initial treatment with dacryoadenectomy and multiple courses of corticosteroids failed to keep his symptoms at bay. Further evaluation revealed florid IgG4 staining. In this context, he was evaluated for image-guided intensity-modulated radiotherapy (IG-IMRT) to the orbit to 20 Gy in 10 fractions. His ophthalmic symptoms resolved. CONCLUSIONS: This treatment experience suggests radiotherapy may be a favorable option for symptom relief in patients with IgG4-related ophthalmic disease not controlled by corticosteroids.
format Online
Article
Text
id pubmed-7492922
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-74929222020-09-21 Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease Sabol, Rachel A. Bubenzer, Virginia Moroz, Krzysztof Halat, Shams Dang, Audrey Ferdinand, Keith Traylor, Angela Boyd, Carol Harris, Kendra Case Rep Ophthalmol Med Case Report BACKGROUND: IgG4-related ophthalmic disease is a rare, newly recognized entity with high failure rates on first-line therapy of systemic corticosteroids and no other proven management options. Case Presentation. Here, we present the clinical course of a patient with IgG4 ophthalmic disease who achieved a favorable response from radiotherapy. Our patient initially presented with a history of recurrent painful flares of orbital inflammation, a pathologic diagnosis follicular lymphoid hyperplasia from a right lacrimal gland biopsy, and MRI imaging noting expansion of the lateral rectus muscle of the right eye. Initial treatment with dacryoadenectomy and multiple courses of corticosteroids failed to keep his symptoms at bay. Further evaluation revealed florid IgG4 staining. In this context, he was evaluated for image-guided intensity-modulated radiotherapy (IG-IMRT) to the orbit to 20 Gy in 10 fractions. His ophthalmic symptoms resolved. CONCLUSIONS: This treatment experience suggests radiotherapy may be a favorable option for symptom relief in patients with IgG4-related ophthalmic disease not controlled by corticosteroids. Hindawi 2020-09-05 /pmc/articles/PMC7492922/ /pubmed/32963860 http://dx.doi.org/10.1155/2020/8873078 Text en Copyright © 2020 Rachel A. Sabol et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sabol, Rachel A.
Bubenzer, Virginia
Moroz, Krzysztof
Halat, Shams
Dang, Audrey
Ferdinand, Keith
Traylor, Angela
Boyd, Carol
Harris, Kendra
Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title_full Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title_fullStr Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title_full_unstemmed Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title_short Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease
title_sort image-guided intensity-modulated radiation therapy for igg4-related ophthalmic disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492922/
https://www.ncbi.nlm.nih.gov/pubmed/32963860
http://dx.doi.org/10.1155/2020/8873078
work_keys_str_mv AT sabolrachela imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT bubenzervirginia imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT morozkrzysztof imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT halatshams imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT dangaudrey imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT ferdinandkeith imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT traylorangela imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT boydcarol imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease
AT harriskendra imageguidedintensitymodulatedradiationtherapyforigg4relatedophthalmicdisease